Curevo Vaccine
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation adjuvanted subunit vaccines to the market quickly.
Series B+ ·
Amount not disclosed in a source on record.
All 3 rounds ↓Acquired by EEli Lilly on for $1.5B · Seattle Times.
Signals
Curevo Vaccine | 1740 days on the record
One step per dated milestone. Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | fundraisingfox.com | |
| Series A | undisclosed | — | flgpartners.com | |
| Series A | undisclosed | businesswire.com |
Timeline
- Acquired by
EEli Lilly · $1.5B
Source: Seattle Times - Website created
Team
GS
George Simeon CEOCL
Chi Li Chief Regulatory OfficerGS
Gregory S. Curhan CFOGD
Guy De La Rosa Chief Medical Officer
Investors
AAdjuvant Capital
- EE&Investment
GGC Biopharma
HHBM Healthcare Investments
JJanus Henderson Investors
MMedicxi
OOrbiMed
RRA Capital Managementlead investor
SSanofi Ventures
Companies like Curevo Vaccine
CCoultreon$125M Series A · Apr 2026LLifeMine Therapeutics$75M Series B+ · Aug 2026
BBionyra$165M Series A · Jun 2026
CCalder Biosciences
FFoRx Therapeutics$50M Series A · Dec 2025
PProtego$130M Series B+ · Dec 2025
Other companies backed by RA Capital Management
AAlethio Therapeutics$90M Series A · Nov 2026
SStar Therapeutics$200M Series B+ · Oct 2026
OOptivolt$32M Series A · Oct 2026
EEstuary Biotherapeutics$103M Series A · Oct 2026
MMMI$125M Series B+ · Oct 2026
AAbcuro$66M Series B+ · Aug 2026
RA Capital Management portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/curevo-vaccine (get a free API key).